13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Valentine Delabie

We are very honoured to count LFB among the Sponsors of BioFIT 2018

Many thanks to LFB for joining BioFIT 2018 as a Contributing Sponsor!

Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare. The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.

The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.

LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries. Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients. Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.

Join key BioFIT 2018 sponsors such as Bayer, Roche, MSD, Boehringer Ingelheim, Pfizer and VIB, to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count LFB among the Sponsors of BioFIT 2018 Read More »

We are very honoured to count Pfizer among the Sponsors of BioFIT 2018

Many thanks to Pfizer for joining BioFIT 2018 as a Bronze Sponsor!

Pfizer is a leading research-based biopharmaceutical company. They apply science and their global resources to deliver innovative therapies that extend and significantly improve lives. They make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands.

Pfizer teams work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Join key BioFIT 2018 sponsors such as Bayer, RocheMSDBoehringer Ingelheim and LFB, to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count Pfizer among the Sponsors of BioFIT 2018 Read More »

Apply to the Licensing Opportunity Presentations

Are you a tech transfer with a ready-to-be-licensed technology? 

Apply to the presentation sessions to:

  • Promote your innovations
  • Receive a speed-monitoring from pharma, biotech, TTO and investors
  • Find partners who could support your project

 

1. Apply
Dedicated to TTO, universities or related structures that have ready-to-be-licensed technologies

 

2. Be selected
A jury of experts will select the most innovative projects

 

3. Exhibit
The selected candidates will benefit from a poster’s exhibition at bioFIT describing their out-licensing opportunities

 

4. Pitch
Presentations of the selected projects to potential industrial partners during BioFIT

 

5. Find partners
The presenters can easily find industrial partners who could in-license their assets

 

Apply to the Licensing Opportunity Presentations

Apply to the Licensing Opportunity Presentations Read More »

Conference Insight

Conference Insight – Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

4 Dec 2018 9:30 – 11:00 am

The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.[/vc_column_text][vc_column_text]They will share their experience:

  • Jan Adams, Managing Director, EMBL Ventures (DE)
  • Jonathan Tobin, Investment Director, Arix Bioscience (UK)
Discover the BioFIT 2018 conference programme

Conference Insight Read More »

They will speak at BioFIT 2018!

Discover the new speakers that will share their vision at BioFIT 2018:

Over 70 international experts from academia, industry and biotech will address issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge.


Alain Chevallier
Life Sciences Partner
Truffle Capital


Marco A. Chacon

Assistant Vice President of Industry Alliances
University of Maryland Baltimore


Rodolphe Besserve

Head SuFT Advisory, Start-up & French Techs
Société Générale Corporate Investments and Banking


Zishan Haroon
Chairman and General Partner
JulzCo

 

Discover all the confirmed speakers
Discover the BioFIT 2018 conference programme

They will speak at BioFIT 2018! Read More »

Apply to the Start-up Slams

Are you an entrepreneur who has created an innovative company (less than 5 years old or to be created)? 

Apply to the presentation sessions to:

  • Promote your innovations
  • Receive a speed-monitoring from pharma, biotech, TTO and investors
  • Find partners who could support your project

 

1. Apply before 30th June
Dedicated to entrepreneurs who have created an innovative company (less than 5 years old or to be created)

2. Be selected
A jury of experts will select the most innovative projects

3. Exhibit
The selected candidates will benefit from a space at BioFIT to hold their one-to-one meetings

4. Pitch
A 6-7 minute presentation of each selected project to potential partners and investors during BioFIT

5. Receive a speed-mentoring
A jury composed of pharma and investors will give feedback and advice to the presenters

6. Be awarded
The most innovative start-up will be awarded by the jury of experts of BioFIT

 

Apply to the Start-up Slams

Apply to the Start-up Slams Read More »

Conference Insight

5 Dec 2018  9:00 – 10:30 am

When addressing the contractual relationships between a university and its spin-off: What are the issues regarding equity, royalties and research income? How do VCs, academic institutions, spin-off management and human resources management of the university interact? What are the main conflicts of interests that can arise from people holding dual positions, in the university and in the start-up?

They will share their experiences:

  • Adrian Ibrahim, Head of technology Transfer, Wellcome Sanger Institute (UK)
  • Caroline Barelle, CEO, Elasmogen (UK)
  • Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
  • Steven J. Klein, Vice President, Business Development IRICoR – Institute for Research in Immunology and Cancer – Commercialization of Research (CA)
Discover the BioFIT 2018 conference programme

Conference Insight Read More »

We are very honoured to count MSD among the Sponsors of BioFIT 2018

Many thanks to MSD for joining BioFIT 2018 as a Bronze Sponsor!

To make a difference in the lives of people globally through innovative medicines, vaccines, and animal health products. MSD is committed to being the premier, research-intensive biopharmaceutical company and is dedicated to providing leading innovations and solutions for today and the future.

Join this key BioFIT 2018 sponsor to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count MSD among the Sponsors of BioFIT 2018 Read More »

Conference insight

Conference insight – Shaping your start-up for an industrial exit or an IPO: Are these choices to be made at the very initial stage?

4 Dec 2018  4:00 – 6:00 pm

Decisions taken at the very initial stage have major consequences for the future development of start-ups with major pitfalls to be avoided. Is it crucial to picture the exit strategy as soon as the company is created? The session relies on its panellists’ stories to go over different approaches of IPO and exits for start-ups.

They will share their experiences:

  • Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK) – Moderator
  • Peter Leonardi, CEO, OmniCyte (US)
  • George Hoffman, Co-founder and CEO, Network Immunology (US)
  • Rodolphe Besserve, Head SuFT Advisory, Start-upd & French Techs, Société Générale Corporate Investments and and Banking (FR)
Discover the BioFIT 2018 conference programme

 

Conference insight Read More »

Scroll to Top
  • No products in the cart.